ClinicalTrials.gg
CompletedNCT02129673Updated Mar 14, 2018

A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension

A Phase 1/2 interventional study of VS101 Insert Dose A and VS101 Insert Dose B in Open Angle Glaucoma and Ocular Hypertension, sponsored by ViSci Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-03-14.

Sponsored by ViSci Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.

Enrollment
149th of 279
77 · median 84
Started
2014
with 20 others
Phase 1/2
18 of 348
2 open now
Registered
148th of 348
by date

Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 149th largest by enrollment of the 279 interventional ones that give a count, is one of 21 that started in 2014, is one of 18 in phase 1/2, and was the 148th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 348 studies in Glaucoma, Open-Angle with a site in United States, or all of them as a file.
02

Study summary

Slow release formulation of latanoprost is compared for safety and pressure-lowering efficacy with topically administration of commercially available latanoprost in patient with glaucoma and ocular hypertension

03

Conditions studied

  • Open Angle Glaucoma
  • Ocular Hypertension

Keywords

  • Glaucoma
  • Intra-ocular pressure
  • Slow Release
  • Controlled release
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18
  • Open angle glaucoma or Ocular Hypertension

Exclusion criteria

Exclusion Criteria:

  • uncontrolled medical conditions
  • wearing of contact lenses
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    VS101 Insert Dose A

    VS101 Insert Dose A placed under the conjunctiva

    Drug: VS101 Insert Dose A

  • Experimental
    VS101 Insert Dose B

    VS101 Insert Dose B placed under the conjunctiva

    Drug: VS101 Insert Dose B

  • Experimental
    VS101 Insert Dose C

    VS101 Insert Dose C placed under the conjunctiva

    Drug: VS101 Insert Dose C

  • Active comparator
    Latanoprost 0.005% eye drops

    Latanoprost 0.005% eye drops administered once daily on the eye

    Drug: Latanoprost 0.005% eye drops

Interventions

  • DrugVS101 Insert Dose A

    Sustained release of latanoprost into the eye

  • DrugVS101 Insert Dose B

    Sustained release of latanoprost into the eye

  • DrugVS101 Insert Dose C

    Sustained release of latanoprost into the eye

  • Latanoprost 0.005% eye drops administered once daily on the eye

06

What researchers measure

Primary outcomes

  1. Intra-ocular pressure

    Time frame: 12 weeks

Secondary outcomes

  1. Intra-ocular pressure

    Time frame: Week 8

  2. Intra-ocular pressure

    Time frame: 4 weeks

07

Study locations

1 site
  • Speciality Eyecare Centre
    Bellevue, Washington, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of May 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2014
First posted
May 2, 2014
Start
May 2014
Primary completionActual
May 2017
CompletionActual
Aug 2017
Last update
Mar 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02129673
Lead sponsor
ViSci Ltd.
Responsible party
Sponsor
First posted
May 2, 2014
Start date
May 2014
Primary completion
May 2017
Completion
Aug 2017
Last update
Mar 14, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion